| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H16F4N4O2S |
| Molecular Weight | 476.447 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(F)C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(C=C4)C#N)C(F)(F)F
InChI
InChIKey=JPQFGMYHKSKKGW-UHFFFAOYSA-N
InChI=1S/C22H16F4N4O2S/c1-28-18(31)15-6-5-14(10-17(15)23)30-20(33)29(19(32)21(30)7-2-8-21)13-4-3-12(11-27)16(9-13)22(24,25)26/h3-6,9-10H,2,7-8H2,1H3,(H,28,31)
| Molecular Formula | C22H16F4N4O2S |
| Molecular Weight | 476.447 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
RD 162 was optimized from a screen for non-steroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. RD 162 binds
to the androgen receptor with greater relative affinity than the clinically used antiandrogen
bicalutamide, reduce the efficiency of its nuclear translocation and impair both DNA binding to
androgen response elements and recruitment of coactivators. RD 162 is orally
available and induce tumor regression in mouse models of castration-resistant human prostate cancer.